Intra-operative Visualization of Urinary Tract Integrity

This diagnostic agent is commonly used in complex surgical procedures—including urological and gynecological operations—to address the critical procedural need for visualization. It is commonly used to help with the assessment of key anatomical structures, particularly when functional stability becomes affected. It is applied when a surgical team requires confirmation of the proper location and structural integrity of these structures. The dye is commonly used in situations involving certain distressing symptoms, where additional symptomatic support is needed. The dye's clear blue contrast may assist with addressing potential risks to the urinary tract during surgical procedures, where symptoms linked to organ-specific functional stress may occur.

Reducing Symptomatic Burden in High-Risk Contexts

The primary benefit contributes to improved general well-being during symptomatic phases and supports patients during difficult episodes by easing distress. By facilitating the real-time assessment of structures, the dye may assist with the timely identification of risks, which may be part of supportive symptom management. It can assist with maintaining functional stability and supports patients during episodes of heightened discomfort, ultimately contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relevant for Functional Stress

Who can and cannot use Indigotindisulfonate Sodium

Official regulatory documentation defines eligibility for this diagnostic dye based on specific patient populations, physiological status, and contraindications.

Contraindicated Populations

The dye is strictly contraindicated for any patient with a known hypersensitivity to Indigotindisulfonate sodium or any component of the formulation. This is an absolute exclusion set by regulatory bodies.

Age- and Organ-Specific Eligibility

• Adults: The dye is indicated for use only in adults following urological and gynecological procedures.
• Pediatric Use: The safety and effectiveness have not been established in pediatric patients according to official labeling.
• Severe Renal Impairment: Use is not recommended in individuals with severe renal impairment (eGFR < 30 mL/min) due to the dye's primary excretion pathway.

Conditional Use and Restrictions

Patients with pre-existing cardiovascular conditions, such as hypertension or heart rate/conduction disorders, are defined in regulatory documents as a population requiring close cardiac monitoring. Regarding pregnancy, use is generally not recommended, and data on first-trimester risk are considered insufficient. For lactating women, transfer into breastmilk is expected to be low, but the full prescribing information must be consulted prior to use.

Interactions with Other Medicines and Products

Official regulatory information for Indigotindisulfonate Sodium (Индигокармин) focuses on procedural interference and risks in specific patient populations, rather than standard drug-drug interaction tables.

Procedural and Monitoring Interference

The dye has been documented to interfere with light absorption, transiently affecting pulse oximetric methods during its administration. Healthcare professionals should be aware of this potential for interference with patient monitoring equipment.

Interaction-Related Risks and Constraints

The most significant interaction consideration relates to the dye's potential to cause vasoconstriction. Patients who are concurrently taking medications that cause bradycardia (a slow heart rate) may be at an increased risk for adverse cardiovascular effects. These risks include elevated blood pressure, hypotension, and bradycardia, requiring close monitoring in this patient group.

Physical Compatibility

To maintain the quality and stability of the product, official labeling requires that Indigotindisulfonate Sodium not be administered using infusion assemblies that have been used with other diluents or drugs. Any portion of the product that is not used immediately upon preparation must be discarded.

No specific medicinal product categories are routinely listed in labeling as being subject to pharmacokinetic (e.g., CYP enzyme) or transporter-mediated interactions with this dye.

Interference with Endothelial Nitric Oxide Signaling

Индигокармин (Indigocarmine) exerts its primary pharmacodynamic effect by interfering with the Nitric Oxide (NO) signaling pathway in the vasculature. The compound acts as an inhibitor, impacting the generation or release of NO from endothelial cells and potentially inhibiting the NO-activated enzyme soluble guanylate cyclase (sGC) in the underlying smooth muscle. The resulting disruption of NO-mediated vasodilation leads to a net increase in systemic vascular resistance and a transient, acute increase in systemic blood pressure (pressor effect).

Passive Filtration and Excretion

Physically, the dye is rapidly cleared from the circulation. Due to its high water solubility, it is excreted largely unchanged by the kidneys via passive glomerular filtration, enabling its rapid visualization in the urinary tract. This passive clearance is non-metabolic and determines the compound's use as a physical tracer.

Baroreflex-Mediated Cardiac Response

The acute rise in blood pressure resulting from peripheral vasoconstriction triggers the baroreflex arc. This compensatory physiological mechanism mediates a reflex slowing of the heart rate (bradycardia), influencing the overall transient cardiovascular profile.

Indigo Carmine (indigotindisulfonate sodium) Injection is a diagnostic dye administered by a healthcare professional in a clinical setting. It is primarily used as a visualization aid in the cystoscopic assessment of the integrity of the ureters following urological and gynecological surgical procedures in adults, but it has also been employed to localize ureteral orifices during cystoscopy and ureteral catheterization.

Dosage and Administration

The recommended adult dosage is typically 5 mL of the 0.8% solution (40 mg Indigotindisulfonate Sodium) administered as a slow intravenous (IV) injection over 1 minute. A second ampoule may be administered 20 to 30 minutes after the initial injection if deemed necessary by the physician.

Important Precautions:

• Monitoring: Blood pressure and cardiac rhythm must be closely monitored during and immediately following the injection due to the potential for severe or life-threatening cardiovascular reactions, including bradycardia and hypertension.
• Preparation: The solution must not be diluted or mixed with other drugs or diluents prior to injection. The contents of the ampule must be immediately withdrawn through a 5-micron filter needle/straw or smaller to ensure no particulates are administered. Any unused portion must be discarded immediately after opening the ampule.
• Renal Function: Indigo Carmine is generally not recommended for use in patients with a severely decreased estimated glomerular filtration rate (eGFR) below 30 mL/min, as the onset of the dye's appearance in the urine may be delayed or impaired.

Индигокармин: Recent Clinical Evidence

Indigotindisulfonate sodium (commonly known as Indigo Carmine) is a water-soluble dye primarily used as a diagnostic aid to visualize the urinary tract during surgical procedures. Its historical use as a renal function test has largely been superseded by its application in identifying ureteral and bladder integrity.

Key Areas of Diagnostic Application

Clinical evidence supports the agent's utility in several surgical contexts, focusing on its rapid excretion by the kidneys, which results in the temporary blue discoloration of urine.

Safety and Comparative Data

A 2022 meta-analysis evaluated the diagnostic performance of Indigo Carmine for detecting ureteral injury in abdominal and pelvic surgery, reporting a high sensitivity (96%) and specificity (100%). Although considered effective, the agent has been associated with transient side effects such as temporary hypertension and bradycardia (slowed heart rate) in some patients.

Alternative imaging techniques and dyes, such as methylene blue and indocyanine green, have been explored, particularly during periods of Indigo Carmine shortage. These alternatives have distinct safety profiles and mechanisms of action, requiring careful clinical consideration.

Common questions about Индигокармин (FAQ)

Q: Does this medicine make you sleepy?

According to official product information, somnolence (sleepiness) and dizziness are listed as very common adverse reactions. This means that these effects are frequently reported in regulatory documents.

Q: Can I stop taking it suddenly?

Regulatory documents indicate that this medicine should be tapered gradually before stopping completely. Abrupt or rapid discontinuation may increase the risk of certain symptoms, such as seizures or other signs of withdrawal.

Q: Is it safe long-term?

Official product information addresses long-term use by listing potential side effects and required monitoring. The comprehensive listing of known effects and warnings, such as monitoring for peripheral edema, weight gain, and changes in suicidal thoughts or behavior, informs the understanding of long-term use.

Q: Can children 2 years old use it?

For most of the approved adult indications, the safety and effectiveness of this medicine have not been established in individuals under the age of 18 years. Therefore, its use in young children is typically not addressed or is not within the approved indications according to regulatory guidelines.

How to Store and Dispose of Индигокармин?

Official regulatory guidelines define specific conditions for storing and disposing of this medicinal product, particularly the solution for injection.

Storage Conditions

• Unopened Product: The unopened solution for injection does not require any special temperature storage conditions.
• Protection: The product should be kept in a dry place and is considered light sensitive. It must be kept in its original, securely sealed container.
• In-Use Stability: Once an ampoule is opened, the solution must be used immediately to maintain stability and integrity.

Handling and Disposal

• Handling: The substance must be kept away from strong oxidizing agents and strong alkalis.
• Disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements for approved waste disposal. The product must be kept away from drains, surface, and ground water to prevent environmental contamination.